Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
13 09 2022
Historique:
received: 16 03 2022
accepted: 01 06 2022
pubmed: 12 7 2022
medline: 1 9 2022
entrez: 11 7 2022
Statut: ppublish

Résumé

Allogenic hematopoietic cell transplantation (alloHCT) is a well-established curative modality for acute lymphoblastic leukemia (ALL), yet large amounts of data describing alloHCT outcomes in Philadelphia (Ph)-like ALL are lacking. We retrospectively analyzed archived DNA samples from consecutive adults with B-cell Ph-negative ALL who underwent alloHCT in complete remission (CR) (n = 127) at our center between 2006 and 2020. Identification of fusions associated with Ph-like ALL was performed using cumulative results from RNA-seq, conventional cytogenetics, fluorescence in situ hybridization, and whole genome array studies. Fusions associated with Ph-like ALL were detected in 56 (44%) patients, of whom 38 were carrying CRLF2r. Compared with other non-Ph-like ALL (n = 71), patients with fusions associated with Ph-like ALL were more frequently Hispanic (P = .008), were less likely to carry high-risk cytogenetics (P < .001), and were more likely to receive blinatumomab prior to HCT (P = .019). With the median followup of 3.5 years, patients with Ph-like ALL fusions had comparable posttransplant outcomes compared with other B-cell ALL: 3-year relapse-free survival (RFS) (41% vs 44%; P = .36), overall survival (OS) (51% vs 50%; P = .59), and relapse (37% vs 31%; P = .47). In multivariable analysis, age (P = .023), disease status at the time of transplant (P < .001), and donor type (P = .015) influenced OS. RFS (primary endpoint) was significantly influenced by disease status (P < .001) and conditioning regimen intensity (P = .014). In conclusion, our data suggest that alloHCT consolidation results in similarly favorable survival outcomes in adult patients with Ph-like fusions and other high-risk B-cell ALL.

Identifiants

pubmed: 35816633
pii: 485833
doi: 10.1182/bloodadvances.2022007597
pmc: PMC9631622
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

4936-4948

Subventions

Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Blood. 2012 Oct 25;120(17):3510-8
pubmed: 22955920
Blood. 2012 Aug 30;120(9):1868-76
pubmed: 22442346
Blood. 2010 Feb 18;115(7):1394-405
pubmed: 19880498
Leukemia. 2017 Apr;31(4):981-984
pubmed: 27932787
Blood. 2010 Jan 14;115(2):206-14
pubmed: 19897583
Bone Marrow Transplant. 2021 Jul;56(7):1746-1749
pubmed: 33767403
Biol Blood Marrow Transplant. 2016 Jul;22(7):1212-1217
pubmed: 27044907
Blood. 2017 Jun 22;129(25):3352-3361
pubmed: 28408464
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Blood. 2010 Jul 1;115(26):5312-21
pubmed: 20139093
Blood. 2021 Jan 28;137(4):471-484
pubmed: 32881995
Leuk Res. 2021 May;104:106579
pubmed: 33831656
Blood. 2009 Feb 5;113(6):1375-82
pubmed: 18988865
Leuk Lymphoma. 2019 Nov;60(11):2832-2834
pubmed: 31014138
Nat Genet. 2013 Dec;45(12):1494-8
pubmed: 24141364
Blood. 2017 Feb 2;129(5):572-581
pubmed: 27919910
Oncotarget. 2018 May 1;9(33):22872-22885
pubmed: 29796158
J Clin Oncol. 2017 Feb;35(4):394-401
pubmed: 27870571
N Engl J Med. 2014 Dec 4;371(23):2235
pubmed: 25470705
Bone Marrow Transplant. 2021 Aug;56(8):1953-1963
pubmed: 33824439
Blood. 2015 May 7;125(19):3033-4
pubmed: 25953979
Blood. 2022 Mar 24;139(12):1908-1919
pubmed: 34914826
Blood. 2017 Jan 12;129(2):177-187
pubmed: 27777238
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766

Auteurs

Ibrahim Aldoss (I)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Dongyun Yang (D)

Department of Computational and Quantitative Medicine.

Vanina Tomasian (V)

Department of Pathology, and.

Sally Mokhtari (S)

Department of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, CA.

Ryan Jackson (R)

Department of Pathology, and.

Zhaohui Gu (Z)

Department of Computational and Quantitative Medicine.

Milhan Telatar (M)

Department of Pathology, and.

Hooi Yew (H)

Department of Pathology, and.

Monzr M Al Malki (MM)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Amandeep Salhotra (A)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Samer Khaled (S)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Haris Ali (H)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Ahmed Aribi (A)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Karamjeet S Sandhu (KS)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Matthew Mei (M)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Shukaib Arslan (S)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Paul Koller (P)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Andrew Artz (A)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Patricia Aoun (P)

Department of Pathology, and.

Dongqing Gu (D)

Department of Pathology, and.

David Snyder (D)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Forrest M Stewart (FM)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Peter Curtin (P)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Anthony S Stein (AS)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Raju Pillai (R)

Department of Pathology, and.

Guido Marcucci (G)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Stephen J Forman (SJ)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Vinod Pullarkat (V)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Ryotaro Nakamura (R)

Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research.

Michelle Afkhami (M)

Department of Pathology, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH